TY - JOUR
T1 - Neurological symptoms and complications in predominantly hospitalized COVID-19 patients
T2 - Results of the European multinational Lean European Open Survey on SARS-Infected Patients (LEOSS)
AU - the LEOSS Study Group
AU - Kleineberg, Nina N.
AU - Knauss, Samuel
AU - Gülke, Eileen
AU - Pinnschmidt, Hans O.
AU - Jakob, Carolin E.M.
AU - Lingor, Paul
AU - Hellwig, Kerstin
AU - Berthele, Achim
AU - Höglinger, Günter
AU - Fink, Gereon R.
AU - Endres, Matthias
AU - Gerloff, Christian
AU - Klein, Christine
AU - Stecher, Melanie
AU - Classen, Annika Y.
AU - Rieg, Siegbert
AU - Borgmann, Stefan
AU - Hanses, Frank
AU - Rüthrich, Maria M.
AU - Hower, Martin
AU - Tometten, Lukas
AU - Haselberger, Martina
AU - Piepel, Christiane
AU - Merle, Uta
AU - Dolff, Sebastian
AU - Degenhardt, Christian
AU - Jensen, Björn Erik O.
AU - Vehreschild, Maria
AU - Erber, Johanna
AU - Franke, Christiana
AU - Warnke, Clemens
AU - Spinner, Christoph
AU - Hanses, Frank
AU - Lanzster, Julia
AU - Borgmann, Stefan
AU - Jensen, Björn
AU - Vehreschild, Maria
AU - Hower, Martin
AU - Rüthrich, Maria Madeleine
AU - Rieg, Siegbert
AU - Rothfuss, Katja
AU - Piepel, Christiane
AU - Wyen, Christopf
AU - Römmele, Christoph
AU - Eberwein, Lukas
AU - Hellwig, Kerstin
AU - Käding, Kadja
AU - Wille, Kai
AU - Degenhardt, Christian
AU - Haake, Hendrik
N1 - Publisher Copyright:
© 2021 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology.
PY - 2021/12
Y1 - 2021/12
N2 - Background and purpose: During acute coronavirus disease 2019 (COVID-19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real-world data from a multinational registry. Methods: We analyzed COVID-19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS-Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression. Results: A total of 6537 COVID-19 patients (97.7% PCR-confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short-term outcome of COVID-19. Conclusion: Our data on mostly hospitalized COVID-19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short-term outcome. ICB in critical COVID-19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life-threatening systemic viral infection.
AB - Background and purpose: During acute coronavirus disease 2019 (COVID-19) infection, neurological signs, symptoms and complications occur. We aimed to assess their clinical relevance by evaluating real-world data from a multinational registry. Methods: We analyzed COVID-19 patients from 127 centers, diagnosed between January 2020 and February 2021, and registered in the European multinational LEOSS (Lean European Open Survey on SARS-Infected Patients) registry. The effects of prior neurological diseases and the effect of neurological symptoms on outcome were studied using multivariate logistic regression. Results: A total of 6537 COVID-19 patients (97.7% PCR-confirmed) were analyzed, of whom 92.1% were hospitalized and 14.7% died. Commonly, excessive tiredness (28.0%), headache (18.5%), nausea/emesis (16.6%), muscular weakness (17.0%), impaired sense of smell (9.0%) and taste (12.8%), and delirium (6.7%) were reported. In patients with a complicated or critical disease course (53%) the most frequent neurological complications were ischemic stroke (1.0%) and intracerebral bleeding (ICB; 2.2%). ICB peaked in the critical disease phase (5%) and was associated with the administration of anticoagulation and extracorporeal membrane oxygenation (ECMO). Excessive tiredness (odds ratio [OR] 1.42, 95% confidence interval [CI] 1.20–1.68) and prior neurodegenerative diseases (OR 1.32, 95% CI 1.07–1.63) were associated with an increased risk of an unfavorable outcome. Prior cerebrovascular and neuroimmunological diseases were not associated with an unfavorable short-term outcome of COVID-19. Conclusion: Our data on mostly hospitalized COVID-19 patients show that excessive tiredness or prior neurodegenerative disease at first presentation increase the risk of an unfavorable short-term outcome. ICB in critical COVID-19 was associated with therapeutic interventions, such as anticoagulation and ECMO, and thus may be an indirect complication of a life-threatening systemic viral infection.
UR - http://www.scopus.com/inward/record.url?scp=85114762588&partnerID=8YFLogxK
U2 - 10.1111/ene.15072
DO - 10.1111/ene.15072
M3 - Journal articles
C2 - 34411383
AN - SCOPUS:85114762588
SN - 1351-5101
JO - European Journal of Neurology
JF - European Journal of Neurology
ER -